How CRISPR gene editing will treat diseases in future: Nobel-winning Intellia co-founder Jennifer DoudnaCNBC • 06/30/21
Implied Volatility Surging for Intellia Therapeutics (NTLA) Stock OptionsZacks Investment Research • 06/30/21
Intellia Therapeutics Stock Moves Higher After Capital Raise Of $600M Issued At $145/ShareBenzinga • 06/30/21
Cathie Wood's Ark ETFs are surging on big gains in CRISPR gene-editing stocks following the success of first human trialsBusiness Insider • 06/28/21
Intellia Therapeutics soars 58% after its gene-editing CRISPR therapy shows success in first human trialsBusiness Insider • 06/28/21
Intellia Shares Shoot Higher On Promising Biomarker Data From CRISPR/Cas9 Genome Editing CandidateBenzinga • 06/28/21
Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) AmyloidosisGlobeNewsWire • 06/26/21